(IN BRIEF) Sandoz has launched Afqlir®, its biosimilar to aflibercept, across Europe following European Commission approval in 2024. Equivalent in efficacy, safety, and pharmacokinetics to Eylea®, Afqlir® provides a lower-cost treatment option for serious retinal diseases such as nAMD, RVO, … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged aflibercept, Afqlir, anti-VEGF market, biologic medicines, biosimilar portfolio, biosimilars, Christophe Delenta, DME, European Commission approval, European Rollout of Afqlir Marks Major Step in Sandoz Expansion Across Anti-VEGF Ophthalmology Market, Eylea, intravitreal injection, mCNV, nAMD, ophthalmology, retinal diseases, RVO, Sandoz, Sustainable Healthcare, vision loss treatment
(IN BRIEF) Sandoz has announced the retirement of Francisco Ballester, President of Region International, after 34 years of service, effective March 1, 2025. Francisco has been instrumental in expanding business growth and patient access in markets outside North America and … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged appointment, biosimilars, Business Growth, Chief Executive Officer, commercial strategy, Country President, Francisco Ballester, generics, Global Platform Head, Health Management and Policy Advisory Council, leadership, M&A, Miami Herbert Business School, patient access, Peter Stenico, Pro Generika, Region International, retirement, Richard Saynor, Sandoz, Sandoz Austria, Sandoz Executive Committee
Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights leading pipeline of second generation immuno-oncology assets Confirms Sandoz on track for 10 biosimilar filings by … Read the full press release
Posted in Healthcare, Management, Pharma & Biotech, Switzerland
Tagged biosimilars, eye care, Joseph Jimenez, Novartis, oncology
We are supporting research and development into innovative drug treatments in Hungary 7-5-2013 — /europawire.eu/ — For well over 100 years, Hungarian pharmaceutical company Gedeon Richter has been working to improve their clients’ health and quality of life. It has stepped … Read the full press release
Posted in Banks, Business, European Union, Financial, Government, Healthcare, Hungary, Investment, Pharma & Biotech, Science
Tagged Anton Rop, biosimilars, biotechnology, EIB, equity investment, Gedeon Richter, guarantees, immunology, INNOVATION, loans, pharmaceutical company, R&D operation, Risk Sharing Finance Facility, treat cancer, Zsolt Szombathelyi
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?